Niagen's ChromaDex Acquires Nicotinamide Riboside Patents From Queen's University Belfast

MT Newswires Live12-23

Niagen Bioscience (NAGE) said Monday its ChromaDex subsidiary has acquired from Queen's University Belfast the patent portfolio for nicotinamide riboside previously shared or licensed to ChromaDex.

Under an assignment agreement, the university assigned to ChromaDex all of its right, title and interest in the patent rights in exchange for an upfront payment of about $1 million, annual payments of $500,000 and 35,000 British pounds ($47,071) from 2026 through 2038, and one-time payments of $1.5 million and $2 million in 2035 and 2038 respectively, Niagen said in its filing with the US Securities and Exchange Commission.

Niagen said the acquired portfolio consists of the core patents supporting the production, composition and commercial use of nicotinamide riboside.

The assignment agreement, executed by ChromaDex and the university last week, terminated their 2015 licensing and joint ownership agreement, Niagen said.

Shares of Niagen were up more than 7% in recent Monday trading.

Price: 6.98, Change: +0.46, Percent Change: +7.06

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593313431?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 00:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593313431","market":"hk","top_or_hot":-1,"title":"Niagen's ChromaDex Acquires Nicotinamide Riboside Patents From Queen's University Belfast","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> (NAGE) said Monday its ChromaDex subsidiary has acquired from Queen's University Belfast the patent portfolio for nicotinamide riboside previously shared or licensed to ChromaDex.</p><p>Under an assignment agreement, the university assigned to ChromaDex all of its right, title and interest in the patent rights in exchange for an upfront payment of about $1 million, annual payments of $500,000 and 35,000 British pounds ($47,071) from 2026 through 2038, and one-time payments of $1.5 million and $2 million in 2035 and 2038 respectively, Niagen said in its filing with the US Securities and Exchange Commission.</p><p>Niagen said the acquired portfolio consists of the core patents supporting the production, composition and commercial use of nicotinamide riboside.</p><p>The assignment agreement, executed by ChromaDex and the university last week, terminated their 2015 licensing and joint ownership agreement, Niagen said.</p><p>Shares of Niagen were up more than 7% in recent Monday trading.</p><p>Price: 6.98, Change: +0.46, Percent Change: +7.06</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Niagen's ChromaDex Acquires Nicotinamide Riboside Patents From Queen's University Belfast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNiagen's ChromaDex Acquires Nicotinamide Riboside Patents From Queen's University Belfast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-23 00:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> (NAGE) said Monday its ChromaDex subsidiary has acquired from Queen's University Belfast the patent portfolio for nicotinamide riboside previously shared or licensed to ChromaDex.</p><p>Under an assignment agreement, the university assigned to ChromaDex all of its right, title and interest in the patent rights in exchange for an upfront payment of about $1 million, annual payments of $500,000 and 35,000 British pounds ($47,071) from 2026 through 2038, and one-time payments of $1.5 million and $2 million in 2035 and 2038 respectively, Niagen said in its filing with the US Securities and Exchange Commission.</p><p>Niagen said the acquired portfolio consists of the core patents supporting the production, composition and commercial use of nicotinamide riboside.</p><p>The assignment agreement, executed by ChromaDex and the university last week, terminated their 2015 licensing and joint ownership agreement, Niagen said.</p><p>Shares of Niagen were up more than 7% in recent Monday trading.</p><p>Price: 6.98, Change: +0.46, Percent Change: +7.06</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593313431","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593313431","pubTimestamp":1766421739,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Niagen Bioscience  said Monday its ChromaDex subsidiary has acquired from Queen's University Belfast the patent portfolio for nicotinamide riboside previously shared or licensed to ChromaDex.Under an assignment agreement, the university assigned to ChromaDex all of its right, title and interest in the patent rights in exchange for an upfront payment of about $1 million, annual payments of $500,000 and 35,000 British pounds  from 2026 through 2038, and one-time payments of $1.5 million and $2 million in 2035 and 2038 respectively, Niagen said in its filing with the US Securities and Exchange Commission.Niagen said the acquired portfolio consists of the core patents supporting the production, composition and commercial use of nicotinamide riboside.The assignment agreement, executed by ChromaDex and the university last week, terminated their 2015 licensing and joint ownership agreement, Niagen said.Shares of Niagen were up more than 7% in recent Monday trading.Price: 6.98, Change: +0.46, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","NAGE":"Niagen Bioscience"},"translate_title":"Niagen公司ChromaDex从贝尔法斯特女王大学获得烟酰胺核苷专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NAGE":1},"content_text":"Niagen Bioscience (NAGE) said Monday its ChromaDex subsidiary has acquired from Queen's University Belfast the patent portfolio for nicotinamide riboside previously shared or licensed to ChromaDex.Under an assignment agreement, the university assigned to ChromaDex all of its right, title and interest in the patent rights in exchange for an upfront payment of about $1 million, annual payments of $500,000 and 35,000 British pounds ($47,071) from 2026 through 2038, and one-time payments of $1.5 million and $2 million in 2035 and 2038 respectively, Niagen said in its filing with the US Securities and Exchange Commission.Niagen said the acquired portfolio consists of the core patents supporting the production, composition and commercial use of nicotinamide riboside.The assignment agreement, executed by ChromaDex and the university last week, terminated their 2015 licensing and joint ownership agreement, Niagen said.Shares of Niagen were up more than 7% in recent Monday trading.Price: 6.98, Change: +0.46, Percent Change: +7.06","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593313431","isCrawlerRequest":true}